Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that ...

Most of any gains (or lack thereof) from here will be driven by just three factors.

CRISPR is one of this generation’s most profound innovations, with the potential to fundamentally alter the realm of modern day diagnostics and medical treatment. Scientists can use the tool to make ...

The company had fallen out of investor favor; its recovery was impressive.

Anthropic’s claim its AI agents discovered an unusual pattern in viral DNA similar to what’s seen in the gene-editing tool CRISPR Cas-9 has set off controversy.

A new engineered gene-editing system, proven in bacteria and showing promise for use in plants, animals and humans, addresses ...

Experts at the company don't know what the newfound system does, so its potential utility in biology—if any—remains unclear.

Anthropic says 950 Claude agents scanned more than 200,000 reverse transcriptases in 21 hours, identifying a novel system called ART that researchers later validated in a laboratory ...

The limits of Anthropic’s finding also point to a more fundamental issue. What made Crispr revolutionary was that scientists ...

Don't read too much into this year's lackluster performance. Near-term catalysts are firming up.

Banas is associate director of research at the Gene Editing Institute at ChristianaCare, where Kmiec is founder and executive director. The medical promise of CRISPR gene editing can be seen most ...

Gene-editing techniques could soon allow researchers to replace entire genes and engineer complex cellular circuits — if the systems can be delivered safely into cells.